Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not to shabby at all......
Good luck
Blueskies
Thank you all for the great feedback....unfortunately i can not private message reply back.
sounds like exciting things are ahead
blueskies
SNDY
Stay positive
A Presidents Letter soon would be a nice start.
SNDY
blueskies
Chyna9 do yourself a favor. Do a quick scan of the more frequent posters and you should quickly see the pattern.
Use the board as a tool only - certainly don't take investment advice from here....including myself
I wish you great luck though in your research and investments
blueskies
SNDY
here ya go....good luck
http://www.nasdaq.com/symbol/sndy/historical
SNDY
BLUESKIES!
3 days...90 mil +
somebody getting nice chunks!
SNDY
BLUESKIES
Yeah SNDY! great to see so many supporters....exciting days weeks months ahead!
have a great weekend all. go play in the snow. lol
Great DD....Enjoy....so much great info out there.
SNDY
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
Great DD....Enjoy....so much great info out there.
nice to see so many longs here
SNDY
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
Stick around....things might just get exciting.
What lead us here - SNDY
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
Yep....another 90+ million bought!
Getting good now.
See what next has in store.
Unfortunately I don't think I can pin anything...my moderator right have been revoked...lol.....oh well.
Blueskies!
Have a great weekend
SNDY
3rd day of volume coming in
Another 40 mil before close?
Something up??
Until next week all
good luck and blueskies
SNDY
SOON NEWS VERY VERY YES? MMM
What lead us here - SNDY
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
What lead us here - SNDY
Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.
June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.
Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.
Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.
"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.
Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe
Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.
Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.
Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease
Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.
"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.
Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally
Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.
April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610
Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.
Blueskies
SNDY
SNDY -
Health Canada's Medical Device Bureau Completes Evaluation of Solos Endoscopic Instruments for Canada
The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada. The Certification comes at the conclusion of a lengthy Audit with TUV SUD America this past Year. The Audit included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282).
The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.
SNDY
blueskies
"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.
SNDY
blueskies
S N D....Y N E...W S O O N!
Come along and sing a song
and join the jamboree
SNDY
blueskies
#3.... Breakout
longs are patient.....at this point,whats a little more waiting? no biggie....lol......others though seem to be getting nervous...why?....Sleep on it.....what if news actually does come very very very very soon?...probably won't (wink) but what if it does?....hmmm... are they in or out?
couple hundred bucks in this game is no biggie right? risk vs reward at this pps? they're thinking about it....I'm sure....why else hang around? lol....IMO....of course.....it's only money peeps.
SNDY
blueskies
cheers to highflier if he's still out there. Hope all is well and everybody's investments work out for them.
There's our volume again....95 mil.
we'll see - stay tuned
Something is up though....
SNDY
blueskies
Some kind of very very soon positive News regarding Canadian and European expansion.
The news items above will give a good idea.
Maybe something regarding a partnership, buyout, merger, etc
SNDY
Blueskies
4's ....NEWS?
5's... NEWS?
8's ...NEWS?
Let's go SNDY!
Don't forget
Nov 12, 2014 (ACCESSWIRE via COMTEX) -- BOSTON, MA / ACCESSWIRE / November 12, 2014 / Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months
#7 Breakout and moving.
50.3 x 12.3
SNDY
Blueskies
NEWS? The next 2 hours?
Increased Volume??
Stick around - News or No News....you can feel the nerves and excitement....or not...haha
SNDY
blueskies
Another mil bought by a lucky one
42.3 x 20.1
SNDY
BLUESKIES
Breakout boards #1 here we come!
SNDY going up baby!!
Blueskies
Sorry...It might Just be NEWS VERY(1) VERY(2) VERY(3) VERY(4) VERY(5) SOON NEWS.
or not...
Maybe no news again
We'll see
blueskies
SNDY
15 mil?
50 mil?? today??
100 mil?? + We'll see
Bids rising....
News? We'll see
SNDY
blueskies
GOOD NEWS VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY VERY SOON ??
Who knows?
Been a long and not going anywhere.
Make $$? ...cool Lose $$? ...Oh well
Good luck
blueskies
SNDY
95,000,000 to make it go down
15,000 to make it go back up.
ha
cheers
SNDY
blueskies
Volume Preceding Price? We'll see.
SNDY
blueskies baby!
Make that 95 mil or so
Positive News would be great right about now lol
SNDY
blueskies
87 mil just went through.
I was expecting different news haha...
SNDY
blueskies
72 mil today. the volume starting is a nice sign. lets see if we get another day of it. could be the volume before the storm?
SNDY has completed the steps and put things in place over the past 2 years...future news should be pretty positive.
looking forward to the updates.
good luck all
blueskies
SNDY
chilly - you're absolutely right! I just got antsy and was looking for some meaningless entertainment...I guess.
Do over - Going to restart the year off right. No more instigating.
I guess in time the longs will have some information to talk about again. I look forward to positive conversations again.
good luck to you chilly3
blueskies
SNDY
SNDY NEWS VERY VERY SOON?? Stay tuned!
blueskies
SNDY
SNDY news very soon?? Could be
blueskies
SNDY
SNDY news soon?? Maybe
blueskies
SNDY
chilly3 I also agree...Solos has spent the time, money and resources to achieve a certification that will allow for future expansion...Hopefully a partnership or possible take over...News regarding Canada and Europe will come...it's just a matter of time...The positive thing about the delays and lack of news is that the true believers in the company have remained. Patience is key.
SNDY has followed and completed all the steps they said they would.
Has it taken some time to complete?? Of course.
Will it be worth it in the end? I sure believe so.
Let the negative comments commence. :)
good luck to you,
blueskies
SNDY
...talk about meaningless dribble....
HAHA.....jus sayin
SNDY
good luck to all
blueskies
SNDY NEWS SOON
so I heard....and looking forward to a company update
Good luck
blueskies
Long SNDY